```
L1             1 S US 20070161663/PN

L1   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2009 ACS on STN
TI   Drug for treating migraine
ACCESSION NUMBER:         2005:729536  CAPLUS  Full-text
DOCUMENT NUMBER:          143:166695
TITLE:                    Drug for treating migraine
INVENTOR(S):              Takeuchi, Megumi; Takayama, Makoto; Shirakura,
Shiro;
                          Kase, Hiroshi
PATENT ASSIGNEE(S):       Kyowa Hakko Kogyo Co., Ltd., Japan
SOURCE:                   PCT Int. Appl., 21 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 Japanese
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ----------------    ----   --------    -------------------    ----
----
     WO 2005072739        A1    20050811    WO 2005-JP1634
20050128
          W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,
CA, CH,
              CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD,
              GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC,
              LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NA, NI,
              NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
SL, SY,
              TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW, AM,
              AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ,
DE, DK,
              EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL,
PL, PT,
              RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML,
              MR, NE, SN, TD, TG

     FILE 'REGISTRY' ENTERED AT 13:39:41 ON 22 JUL 2009
L2             1 S 861387-31-7/RN
               SET NOTICE 1 DISPLAY
               SET NOTICE LOGIN DISPLAY

     FILE 'REGISTRY' ENTERED AT 13:40:05 ON 22 JUL 2009
L3             1 S 861387-30-6/RN
               SET NOTICE 1 DISPLAY
               SET NOTICE LOGIN DISPLAY

     FILE 'CAPLUS' ENTERED AT 13:40:21 ON 22 JUL 2009
L4             3 S L3
```

```
     FILE 'REGISTRY' ENTERED AT 13:42:54 ON 22 JUL 2009
L5                STRUCTURE UPLOADED
L6            110 S L5 SSS FULL

     FILE 'CAPLUS' ENTERED AT 13:43:50 ON 22 JUL 2009
L7            122 S L6
L8             64 S L7 AND (PY<2004 OR AY<2004 OR PRY<2004)

     FILE 'REGISTRY' ENTERED AT 13:45:08 ON 22 JUL 2009
L9                STRUCTURE UPLOADED
L10            33 S L9 SSS FULL

     FILE 'CAPLUS' ENTERED AT 13:45:48 ON 22 JUL 2009
L11           121 S L10
L12            64 S L11 AND (PY<2004 OR AY<2004 OR PRY<2004)
L13             1 S L11 AND MIGRAINE/IT

     FILE 'REGISTRY' ENTERED AT 13:49:26 ON 22 JUL 2009
                E 31377-40-9/RN
                SET EXPAND CONTINUOUS
L14             1 S E3

     FILE 'CAPLUS' ENTERED AT 13:50:19 ON 22 JUL 2009

     FILE 'REGISTRY' ENTERED AT 13:50:21 ON 22 JUL 2009

     FILE 'REGISTRY' ENTERED AT 13:50:33 ON 22 JUL 2009
                E 155270-99-8/RN
L15             1 S E15

L15  ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2009 ACS on STN
RN   155270-99-8  REGISTRY
ED   Entered STN:  24 May 1994
CN   1H-Purine-2,6-dione, 8-[(1E)-2-(3,4-dimethoxyphenyl)ethenyl]-1,3-
diethyl-
     3,7-dihydro-7-methyl-  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   1H-Purine-2,6-dione, 8-[2-(3,4-dimethoxyphenyl)ethenyl]-1,3-
diethyl-3,7-
     dihydro-7-methyl-, (E)-
OTHER NAMES:
CN   Istradefylline
CN   KW 6002
FS   STEREOSEARCH
MF   C20 H24 N4 O4
CI   COM
SR   CA
LC   STN Files:   ADISINSIGHT, ADISNEWS, AGRICOLA, BIOSIS, BIOTECHNO,
CA,
       CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, EMBASE, IMSPATENTS,
IMSRESEARCH,
       IPA, MEDLINE, PHAR, PROMT, PROUSDDR, RTECS*, SYNTHLINE,
TOXCENTER, USAN,
       USPAT2, USPATFULL
         (*File contains numerically searchable property data)
```

Double bond geometry as shown.



FILE 'REGISTRY' ENTERED AT 13:51:44 ON 22 JUL 2009
E 155270-99-8/RN
L16 1 S E27

FILE 'CAPLUS' ENTERED AT 13:52:28 ON 22 JUL 2009
L17 106 S L16
L18 54 S L17 AND (PY<2004 OR AY<2004 OR PRY<2004)
L19 0 S L17 AND VASODILAT?
L20 1 S L17 AND HEADACHE?

L20 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2009 ACS on STN
TI Super-sweet sugar crystals and syrups for health and method
ACCESSION NUMBER: 2008:72174 CAPLUS Full-text
DOCUMENT NUMBER: 148:143548
TITLE: Super-sweet sugar crystals and syrups for health and
method
INVENTOR(S): Badalov, Constantin
PATENT ASSIGNEE(S): Can.
SOURCE: U.S. Pat. Appl. Publ., 14pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080014331	A1	20080117	US 2006-487933	20060717
CA 2559222	A1	20080117	CA 2006-2559222	20060912

PRIORITY APPLN. INFO.: US 2006-487933 A 20060717

L21 27 S L17 AND BRAIN?
L22 10 S L21 AND (PY<2004 OR AY<2004 OR PRY<2004)

L22 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
TI Xanthine derivatives and salts and compositions for preventing and/or

treating higher brain dysfunction

L22 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
TI A method using (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine
for treating behavioral disorders

L22 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
TI Translating A2A antagonist KW6002 from animal models to parkinsonian
patients

L22 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
TI Methods using adenosine A2A receptor antagonists for treating Parkinson's
disease patients suffering from L-DOPA/dopamine agonist therapy-associated
movement disorders

L22 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
TI Adenosine A2A receptor antagonists combined with neurotrophic activity
compounds in the treatment of Parkinson's disease

L22 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
TI Distribution of adenosine A2A receptor antagonist KW-6002 and its effect
on gene expression in the rat brain

L22 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
TI Neuroprotection by adenosine A2A receptor blockade in experimental models
of Parkinson's disease

L22 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
TI Solubilization and immunoprecipitation of rat striatal adenosine A2A
receptors

L22 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
TI Systemic administration of adenosine A2A receptor antagonist reverses
increased GABA release in the globus pallidus of unilateral
6-hydroxydopamine-lesioned rats: a microdialysis study

L22 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
TI Adenosine A2A receptors modify motor function in MPTP-treated common
marmosets

L23 3 S L17 AND CEREBRAL?
L24 2 S L23 AND (PY<2004 OR AY<2004 OR PRY<2004)
L25 3 S L17 AND MUSCLE?
L26 1 S L25 AND (PY<2004 OR AY<2004 OR PRY<2004)

L26 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2009 ACS on STN
TI Adenosine A2A receptor antagonists for treating restless legs

syndrome or
related disorders
ACCESSION NUMBER: 2004:203674 CAPLUS Full-text
DOCUMENT NUMBER: 140:229467
TITLE: Adenosine A2A receptor antagonists for treating
restless legs syndrome or related disorders
INVENTOR(S): Kase, Hiroshi; Seno, Naoki; Mori, Akihisa; Zhao, Dayao
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co. Ltd., Japan
SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004019949	A1	20040311	WO 2003-US26644	20030827 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

L27 1 S L17 AND SMOOTH?
L28 0 S L27 AND (PY<2004 OR AY<2004 OR PRY<2004)
L29 1 S L17 AND CEREBRO?

L29 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2009 ACS on STN
TI Xanthine derivatives and salts and compositions for preventing and/or
treating higher brain dysfunction
ACCESSION NUMBER: 2005:547543 CAPLUS Full-text
DOCUMENT NUMBER: 143:53542
TITLE: Xanthine derivatives and salts and compositions for
preventing and/or treating higher brain dysfunction

INVENTOR(S): Kase, Hiroshi; Nakagawa, Yutaka; Shiozaki, Shizuo;
Kobayashi, Minoru; Toki, Shinichiro; Seno, Naoki;
Ikeda, Ken
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005056016	A1	20050623	WO 2004-JP18765	20041209

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

L30 2 S L17 AND (NAUSEA OR NAUSEOUS)
L31 1 S L30 AND (PY<2004 OR AY<2004 OR PRY<2004)

L31 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2009 ACS on STN
TI Randomized trial of the adenosine A2A receptor antagonist istradefylline
in advanced PD
ACCESSION NUMBER: 2003:575785 CAPLUS Full-text
DOCUMENT NUMBER: 140:105006
TITLE: Randomized trial of the adenosine A2A receptor antagonist istradefylline in advanced PD
AUTHOR(S): Hauser, Robert A.; Hubble, Jean P.; Truong, Daniel D.
CORPORATE SOURCE: Tampa General Healthcare, and Experimental Therapeutics, University of South Florida, Tampa, FL,
USA

SOURCE: Neurology (2003), 61(3), 297-303
CODEN: NEURAI; ISSN: 0028-3878
PUBLISHER: Lippincott Williams & Wilkins
DOCUMENT TYPE: Journal
LANGUAGE: English
CC 1-11 (Pharmacology)
IT 155270-99-8, Istradefylline
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(adenosine A2A receptor antagonist istradefylline in levodopa-treated
Parkinson disease patients)

AB The aim was to evaluate the safety and efficacy of the adenosine A2A receptor antagonist istradefylline (KW-6002) in patients with levodopa-treated Parkinson's disease (PD) with both motor fluctuations and peak-dose dyskinesias. This was a 12-wk, double-blind, randomized, placebo-controlled, exploratory study in which PD subjects with both motor fluctuations and peak-dose dyskinesias were randomized to treatment with placebo (n = 29), istradefylline up to 20 mg/day (n = 26), or istradefylline up to 40 mg/day (n = 28). There was no prespecified primary outcome measure, and 19 outcome variables were analyzed. As assessed by home diaries, subjects assigned to istradefylline experienced a mean (± SE) reduction in the proportion of awake time spent in the "off" state of 7.1 ± 2.0% compared with an increase of 2.2 ± 2.7% in the placebo group (p = 0.008). There was a decrease in "off" time of 1.2 ± 0.3 h in the istradefylline group compared with an increase of 0.5 ± 0.5 h in the placebo group (p = 0.004). Dyskinesia severity was unchanged, but "on" time with dyskinesia increased in the istradefylline group compared with the placebo group (percent, p = 0.002; hours, p = 0.001). No differences were observed in change in Unified Parkinson's Disease Rating Scale scores or Clin. Global Impression of Change. Twenty-four percent of placebo-assigned subjects and 20% of istradefylline-assigned subjects withdrew from the study. Both dose regimens of istradefylline were generally well tolerated, and nausea was the most common adverse event. Istradefylline was generally well tolerated and reduced "off" time as assessed by home diaries. Severity of dyskinesia was unchanged, but "on" time with dyskinesia increased.

```
L32          0 S L17 AND (PAIN? OR ANESTHETIC OR ANESTHESIA)
L33          1 S L17 AND ANALGES?
L34          0 S L33 AND (PY<2004 OR AY<2004 OR PRY<2004)
L35          0 S L17 AND ?DILAT?
L36          0 S L17 AND (VESSEL?)
L37          2 S L17 AND (BLOOD)
L38          0 S L37 AND (PY<2004 OR AY<2004 OR PRY<2004)
L39       5841 S L17 AND VOMIT? OR (EMETIC OR EMESIS)
L40          0 S L17 AND (VOMIT? OR ?EMETIC OR ?EMESIS)
L41          2 S L17 AND SEROTONIN?
L42          1 S L41 AND (PY<2004 OR AY<2004 OR PRY<2004)


L1           1 S E3
               E CAFFEINE/CN
```

```
L2            1 S E15

     FILE 'CAPLUS' ENTERED AT 15:21:24 ON 22 JUL 2009
L3            7 S L1 AND L2
L4            2 S L3 AND (PY<2004 OR AY<2004 OR PRY<2004)
L5        24673 S L2
L6          118 S L5 AND MIGRAINE?
L7           75 S L6 AND (PY<2004 OR AY,2004 OR PRY<2004)
L8           75 S L6 AND (PY<2004 OR AY<2004 OR PRY<2004)
L9            7 S L6 AND ADENOSINE?
L10           3 S L9 AND (PY<2004 OR AY<2004 OR PRY<2004)

     FILE 'REGISTRY' ENTERED AT 15:28:00 ON 22 JUL 2009
L11             STRUCTURE UPLOADED
L12          33 S L11 SSS FULL

L12  ANSWER 15 OF 64  CAPLUS  COPYRIGHT 2009 ACS on STN
TI   Potential for antipsychotic and psychotomimetic effects of A2A
receptor
     modulation
ACCESSION NUMBER:         2003:904669  CAPLUS  Full-text
DOCUMENT NUMBER:          140:399839
TITLE:                    Potential for antipsychotic and
psychotomimetic
                          effects of A2A receptor modulation
AUTHOR(S):                Weiss, Scott M.; Whawell, Emma; Upton,
Rebecca;
                          Dourish, Colin T.
CORPORATE SOURCE:         Vernalis Research Ltd., Wokingham, RG41 5UA,
UK
SOURCE:                   Neurology (2003), 61(11, Suppl. 6), S88-S93
                          CODEN: NEURAI; ISSN: 0028-3878
PUBLISHER:                Lippincott Williams & Wilkins
DOCUMENT TYPE:            Journal
LANGUAGE:                 English
CC   1-11 (Pharmacology)
IT   58-00-4, Apomorphine 155270-99-8, KW 6002
     RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological
     activity); BIOL (Biological study)
        (KW 6002 and apomorphine effect on prepulse inhibition of
acoustic
        startle reaction in rats)
REFERENCE COUNT:          52    THERE ARE 52 CITED REFERENCES AVAILABLE
FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE
RE FORMAT

L12  ANSWER 17 OF 64  CAPLUS  COPYRIGHT 2009 ACS on STN
TI   A2A antagonist prevents dopamine agonist-induced motor
complications in
     animal models of Parkinson's disease
ACCESSION NUMBER:         2003:903742  CAPLUS  Full-text
DOCUMENT NUMBER:          141:17366
TITLE:                    A2A antagonist prevents dopamine agonist-
induced motor
                          complications in animal models of Parkinson's
disease
```

AUTHOR(S): Bibbiani, F.; Oh, J. D.; Petzer, J. P.; Castagnoli,
N.; Chen, J.-F.; Schwarzschild, M. A.; Chase, T. N.
CORPORATE SOURCE: NINDS, ETB, National Institutes of Health, Bethesda,
MD, USA
SOURCE: Experimental Neurology (2003), 184(1), 285-294
CODEN: EXNEAC; ISSN: 0014-4886
PUBLISHER: Elsevier Science
DOCUMENT TYPE: Journal
LANGUAGE: English
CC 1-11 (Pharmacology)
IT 155270-99-8, KW-6002
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(KW-6002 reduced dyskinesias in combination with apomorphine in parkinsonian primate, reversed shortened motor responses produced by
chronic levodopa treatment, reduced hyperphosphorylation of S845
residue in hemiparkinsonian rat)
REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 27 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN
TI Neurologic drugs
ACCESSION NUMBER: 2002:966169 CAPLUS Full-text
DOCUMENT NUMBER: 139:110860
TITLE: Neurologic drugs
AUTHOR(S): Mealy, N. E.; Castaner, R.; Martin, L.; del Fresno,
M.; Revel, L.; Bayes, M.; Sorbera, L. A.; Cole, P.;
Cullell-Young, M.; Leeson, P. A.; Prous, J.
CORPORATE SOURCE: Spain
SOURCE: Drugs of the Future (2002), 27(9), 879-915
CODEN: DRFUD4; ISSN: 0377-8282
PUBLISHER: Prous Science
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
CC 1-0 (Pharmacology)
IT 89-25-8, Edaravone 504-24-5, Fampridine 37178-37-3, Etilevodopa
49763-96-4, Stiripentol 60940-34-3, Ebselen 68693-11-8, Modafinil
69056-38-8, Sapropterin dihydrochloride 82248-59-7, Tomoxetine hydrochloride 90494-79-4, Xaliproden hydrochloride 107220-28-0,
Cevimeline hydrochloride 120011-70-3, Donepezil hydrochloride
125572-93-2, Rotigotine hydrochloride 129101-54-8, Rivastigmine tartrate
133920-70-4, FK-960 142935-03-3, T-588 144980-77-8, Repinotan

hydrochloride 148553-50-8, Pregabalin 150812-12-7, Retigabine 155270-99-8, KW-6002 161735-79-1, Rasagiline mesylate 161832-65-1, Talampanel 168021-79-2, NXY-059 183619-38-7, CPI-1189 189261-10-7, Natalizumab 192564-13-9, Leteprinim potassium 202825-46-5, Safinamide mesylate 263248-42-6, Zanapezil fumarate 269718-83-4, SLV 308
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(of neurol. drugs)
REFERENCE COUNT: 172 THERE ARE 172 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 30 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN
TI Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease
ACCESSION NUMBER: 2002:90903 CAPLUS Full-text
DOCUMENT NUMBER: 136:277364
TITLE: Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease
AUTHOR(S): Ikeda, Ken; Kurokawa, Masako; Aoyama, Shiro; Kuwana, Yoshihisa
CORPORATE SOURCE: Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co., Ltd., Shizuoka, 411-8731, Japan
SOURCE: Journal of Neurochemistry (2002), 80(2), 262-270
CODEN: JONRA9; ISSN: 0022-3042
PUBLISHER: Blackwell Publishing Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
CC 14-10 (Mammalian Pathological Biochemistry)
IT 155270-99-8, KW-6002
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(adenosine A2A receptor antagonist neuroprotective property in exptl. models of Parkinson's disease)
REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 32 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN
TI New developments in A1 and A2 adenosine receptor antagonists
ACCESSION NUMBER: 2001:915602 CAPLUS Full-text
DOCUMENT NUMBER: 136:303408
TITLE: New developments in A1 and A2 adenosine receptor antagonists

AUTHOR(S): Kiec-Kononowicz, K.; Drabczynska, A.; Pekala, E.;
Michalak, B.; Miller, C. E.; Schumacher, B.;
Karolak-Wojciechowska, J.; Duddeck, H.; Rockitt, S.;
Wartchow, R.
CORPORATE SOURCE: IUPAC Commission, Medical College, Department of
Chemical Technology of Drugs, Jagiellonian University,
Krakow, PL 30-688, Pol.
SOURCE: Pure and Applied Chemistry (2001), 73(9), 1411-1420
CODEN: PACHAS; ISSN: 0033-4545
PUBLISHER: International Union of Pure and Applied Chemistry
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
CC 1-0 (Pharmacology)
Section cross-reference(s): 28
IT 19264-87-0P 19264-88-1P 19410-42-5P 49687-20-9P 49687-21-0P
97554-89-7P 102146-07-6P 121524-18-3P, Fk 453 131185-37-0P, Fk 838
136199-02-5P, Kw 3902 139180-30-6P, Zm 241385 141807-96-7P, KW 17837
155270-99-8P, Kw 6002 156547-56-7P 160098-96-4P, Sch 58261
166374-48-7P, Cvt 124 175097-37-7P, Wrc 0571 232252-63-0P
232255-03-7P 261717-18-4P, Msx 2 261717-23-1P, Msx 3 264622-53-9P,
MRS 1706 321907-04-4P 410070-40-5P 410070-41-6P 410070-42-7P
410070-43-8P 410070-44-9P 410070-45-0P 410070-46-1P 410070-47-2P
410070-48-3P 410070-49-4P
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(new developments in A1 and A2 adenosine receptor antagonists)
REFERENCE COUNT: 62 THERE ARE 62 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 33 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN
TI Neuroprotection by caffeine and A2A adenosine receptor inactivation in a
model of Parkinson's disease
ACCESSION NUMBER: 2001:910700 CAPLUS Full-text
DOCUMENT NUMBER: 136:31603
TITLE: Neuroprotection by caffeine and A2A adenosine receptor
inactivation in a model of Parkinson's disease
AUTHOR(S): Chen, Jiang-Fan; Xu, Kui; Petzer, Jacobus P.; Staal,
Roland; Xu, Yue-Hang; Beilstein, Mark; Sonsalla,

Patricia K.; Castagnoli, Kay; Castagnoli, Neal, Jr.;
Schwarzschild, Michael A.
CORPORATE SOURCE: Molecular Neurobiology Laboratory, Department of
Neurology, Massachusetts General Hospital, Charlestown, MA, 02129, USA
SOURCE: Journal of Neuroscience (2001), 21(10), RC143/1-RC143/6
CODEN: JNRSDS; ISSN: 0270-6474
PUBLISHER: Society for Neuroscience
DOCUMENT TYPE: Journal
LANGUAGE: English
CC 1-11 (Pharmacology)
IT 14114-46-6, 3,7-Dimethyl-1-propargyl xanthine 102146-07-6, 8-Cyclopentyl-1,3-dipropylxanthine 155270-99-8, KW-6002 160098-96-4, SCH 58261
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(effect of caffeine and adenosine antagonists in model of Parkinson's disease)
REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 36 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN
TI Adenosine A2A receptor antagonists are potential antidepressants: evidence
based on pharmacology and A2A receptor knockout mice
ACCESSION NUMBER: 2001:688889 CAPLUS Full-text
DOCUMENT NUMBER: 136:48351
TITLE: Adenosine A2A receptor antagonists are potential
antidepressants: evidence based on pharmacology and
A2A receptor knockout mice
AUTHOR(S): El Yacoubi, Malika; Ledent, Catherine; Parmentier,
Marc; Bertorelli, Rosalia; Ongini, Ennio; Costentin,
Jean; Vaugeois, Jean-Marie
CORPORATE SOURCE: UMR 6036 CNRS, IFRMP 23, U.F.R. de Medecine and
Pharmacie, Rouen, 76183, Fr.
SOURCE: British Journal of Pharmacology (2001), 134(1), 68-77
CODEN: BJPCBM; ISSN: 0007-1188
PUBLISHER: Nature Publishing Group
DOCUMENT TYPE: Journal
LANGUAGE: English
CC 1-11 (Pharmacology)
IT 139180-30-6, ZM 241385 155270-99-8, KW 6002 160098-96-4, SCH 58261
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)

(adenosine A2A receptor antagonists are potential antidepressants in
A2A receptor knockout mice)
REFERENCE COUNT: 64 THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 39 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN
TI KW-6002
ACCESSION NUMBER: 2001:258391 CAPLUS Full-text
DOCUMENT NUMBER: 135:189568
TITLE: KW-6002
AUTHOR(S): Rabasseda, X.; Sorbera, L. A.; Martin, L.; Leeson, P.
A.; Castaner, J.
CORPORATE SOURCE: Prous Science, Barcelona, 08080, Spain
SOURCE: Drugs of the Future (2001), 26(1), 20-24
CODEN: DRFUD4; ISSN: 0377-8282
PUBLISHER: Prous Science
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
CC 1-0 (Pharmacology)
IT 155270-99-8P, KW-6002
RL: BAC (Biological activity or effector, except adverse); BPR (Biological
process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(antiparkinsonian-antidepressant adenosine A2A antagonist KW-6002)
REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 47 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN
TI Preventives and remedies for sleep disturbance
ACCESSION NUMBER: 1999:404845 CAPLUS Full-text
DOCUMENT NUMBER: 131:39753
TITLE: Preventives and remedies for sleep disturbance
INVENTOR(S): Shimada, Junichi; Ichikawa, Shunji; Suzuki, Fumio
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9930715	A1	19990624	WO 1998-JP5639	19981214 <--
W: AU, BG, BR, CA, CN, CZ, HU, IL, JP, KR, MX, NO, NZ, PL,				

RO, SG,
SI, SK, UA, US, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,
MC, NL,
PT, SE
AU 9915070 A 19990705 AU 1999-15070
19981214 <--
JP 2009143929 A 20090702 JP 2009-21
20090105 <--
PRIORITY APPLN. INFO.: JP 1997-344826 A
19971215 <--
JP 2000-538697 A3
19981214 <--
WO 1998-JP5639 W
19981214 <--
OTHER SOURCE(S): MARPAT 131:39753
IC ICM A61K031-52
ICS C07D473-04; C07D473-20; C07D473-22
CC 1-11 (Pharmacology)
Section cross-reference(s): 63
IT 155270-99-8
RL: BAC (Biological activity or effector, except adverse); BSU
(Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological
study); USES
(Uses)
(preventives and remedies for sleep disturbance)
REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE
FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE
RE FORMAT

L12 ANSWER 50 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN
TI Therapeutic agent for neural degeneration
ACCESSION NUMBER: 1999:194000 CAPLUS Full-text
DOCUMENT NUMBER: 130:218320
TITLE: Therapeutic agent for neural degeneration
INVENTOR(S): Shimada, Junichi; Kurokawa, Masako; Ikeda,
Ken;
Susuki, Fumio; Kuwana, Yoshihisa
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9912546	A1	19990318	WO 1998-JP3980	
19980904 <--				

W: AU, BG, BR, BY, CN, CZ, HU, IL, JP, KR, MX, NO, NZ, PL,
RO, SG,
SI, SK, UA, US, VN, AM, AZ, KG, KZ, MD, RU, TJ, TM
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,

MC, NL,
PT, SE
AU 9889976 A 19990329 AU 1998-89976
19980904 <--
AU 734138 B2 20010607
EP 1016407 A1 20000705 EP 1998-941725
19980904 <--
EP 1016407 B1 20060510
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,
MC, PT,
IE, SI, LT, LV, FI, RO, CY
EP 1666041 A2 20060607 EP 2006-5220
19980904 <--
EP 1666041 A3 20080402
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,
MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL
AT 325610 T 20060615 AT 1998-941725
19980904 <--
ES 2264210 T3 20061216 ES 1998-941725
19980904 <--
CA 2299909 A1 20010902 CA 2000-2299909
20000302 <--
CA 2299909 C 20080513
US 20030158214 A1 20030821 US 2000-486823
20000303 <--
US 6727259 B2 20040427
US 20040229888 A1 20041118 US 2003-692930
20031027 <--
US 7115614 B2 20061003
US 20060258688 A1 20061116 US 2006-488623
20060719 <--
US 20080207649 A1 20080828 US 2008-112801
20080430 <--
JP 2009102334 A 20090514 JP 2008-307355
20081202 <--
PRIORITY APPLN. INFO.: JP 1997-240565 A
19970905 <--
EP 1998-941725 A3
19980904 <--
JP 2000-510443 A3
19980904 <--
WO 1998-JP3980 W
19980904 <--
US 2000-486823 A3
20000303 <--
US 2003-692930 A3
20031027 <--
US 2006-488623 B3
20060719
OTHER SOURCE(S): MARPAT 130:218320
IC ICM A61K031-52
ICS C07D473-04; C07D473-20; C07D473-22
CC 1-11 (Pharmacology)
Section cross-reference(s): 63
IT 51389-37-8 141807-96-7 155270-99-8 155272-00-7
RL: BAC (Biological activity or effector, except adverse); BSU

(Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological
study); USES
(Uses)
(therapeutic agent for neural degeneration)
REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE
FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE
RE FORMAT

L12 ANSWER 55 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN
TI Adenosine A2A antagonists with potent anti-cataleptic activity
ACCESSION NUMBER: 1997:686352 CAPLUS Full-text
DOCUMENT NUMBER: 128:30029
ORIGINAL REFERENCE NO.: 128:5737a,5740a
TITLE: Adenosine A2A antagonists with potent anti-
cataleptic
activity
AUTHOR(S): Shimada, Junichi; Koike, Nobuaki; Nonaka,
Hiromi;
Shiozaki, Shizuo; Yanagawa, Koji; Kanda,
Tomoyuki;
Kobayashi, Hiroyuki; Ichimura, Michio;
Nakamura, Joji;
Kase, Hiroshi; Suzuki, Fumio
CORPORATE SOURCE: Drug Discovery Research Laboratories,
Pharmaceutical
Research Institute, Kyowa Hakko Kogyo Co.,
Ltd.,
Sunto, 411, Japan
SOURCE: Bioorganic & Medicinal Chemistry Letters (1997
), 7(18), 2349-2352
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
CC 1-3 (Pharmacology)
Section cross-reference(s): 28
IT 141807-86-5P 141807-94-5P 141807-96-7P, Kf 17837 141807-98-
9P
141808-00-6P 147700-40-1P, 1H-Purine-2,6-dione,
1,3-diethyl-3,7-dihydro-7-methyl-8-[2-(3,4,5-
trimethoxyphenyl)ethenyl]-,
(E)- 147700-52-5P 147700-54-7P 151539-19-4P 151539-21-8P
151539-23-0P, 1H-Purine-2,6-dione,
8-[2-(2,4-dimethoxyphenyl)ethenyl]-3,7-dihydro-7-methyl-1,3-
dipropyl-,
(E)- 151539-31-0P, 1H-Purine-2,6-dione,
8-[2-(3,5-dimethoxyphenyl)ethenyl]-3,7-dihydro-7-methyl-1,3-
dipropyl-,
(E)- 151539-39-8P 155270-99-8P 155271-03-7P,
1H-Purine-2,6-dione, 8-[2-(2,4-dimethoxyphenyl)ethenyl]-1,3-
diethyl-3,7-
dihydro-7-methyl-, (E)- 155271-05-9P 155271-07-1P
155271-11-7P
RL: BAC (Biological activity or effector, except adverse); BPR
(Biological

process); BSU (Biological study, unclassified); PRP (Properties); SPN
(Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);
PREP (Preparation); PROC (Process); USES (Uses)
(preparation of styrylxanthines as adenosine A2A antagonists with potent
anti-cataleptic activity in relation to structure)
REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 59 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN
TI Preparation of 8-styryl-1,3,7-trialkylxanthine derivatives as A2-selective
adenosine receptor antagonists
ACCESSION NUMBER: 1995:446631 CAPLUS Full-text
DOCUMENT NUMBER: 122:213859
ORIGINAL REFERENCE NO.: 122:39087a,39090a
TITLE: Preparation of 8-styryl-1,3,7-trialkylxanthine derivatives as A2-selective adenosine receptor antagonists
INVENTOR(S): Jacobson, Kenneth A.; Karton, Yishai; Gallo-Rodriguez,
Carola; Fischer, Bilha; Van Galen, Philip J. M.;
Maillard, Michel
PATENT ASSIGNEE(S): United States Dept. of Health and Human Services, USA
SOURCE: PCT Int. Appl., 97 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9425462	A1	19941110	WO 1994-US4876	19940503 <--
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9467811	A	19941121	AU 1994-67811	19940503 <--
US 5861405	A	19990119	US 1994-335108	19941107 <--
PRIORITY APPLN. INFO.:			US 1993-57086	A 19930503 <--
			WO 1994-US4876	W 19940503 <--

OTHER SOURCE(S): MARPAT 122:213859
IC ICM C07D473-08
ICS C07D473-12; C07D473-06; A61K031-52
CC 26-9 (Biomolecules and Their Synthetic Analogs)

Section cross-reference(s): 1
IT 51389-37-8P 99765-13-6P 141807-86-5P 141807-96-7P 147699-95-4P
147699-98-7P 147700-00-3P 147700-02-5P 147700-04-7P 147700-05-8P
147700-06-9P 147700-07-0P 147700-08-1P 147700-10-5P 147700-13-8P
147700-15-0P 147700-17-2P 147700-19-4P 147700-21-8P 147700-23-0P
147700-26-3P 147700-27-4P 147700-28-5P 147700-29-6P 147700-33-2P
147700-35-4P 147700-36-5P 147700-37-6P 147700-38-7P
147700-40-1P 147700-41-2P 147700-42-3P 147700-44-5P
147700-46-7P 147700-50-3P 147700-52-5P 147700-54-7P 147700-55-8P
151539-31-0P 161826-76-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 8-styryl-1,3,7-trialkylxanthine derivs. as A2-selective
adenosine receptor antagonists)
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 60 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN
TI (Styryl)xanthine-derivatives adenosine A2 receptor antagonists
ACCESSION NUMBER: 1995:168999 CAPLUS Full-text
DOCUMENT NUMBER: 122:81388
ORIGINAL REFERENCE NO.: 122:15467a,15470a
TITLE: (Styryl)xanthine-derivatives adenosine A2 receptor
antagonists
INVENTOR(S): Suzuki, Fumio; Shimada, Junichi; Koike, Nobuaki; Kase,
Hiroshi; Nakamura, Joji; Shiozaki, Shizaki; Nonaka,
Hiromi
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
SOURCE: Can. Pat. Appl., 69 pp.
CODEN: CPXXEB
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2112031	A1	19940625	CA 1993-2112031	19931221 <--
JP 06239862	A	19940830	JP 1993-316132	19931216 <--

JP 3165769 B2 20010514
NO 9304792 A 19940627 NO 1993-4792
19931223 <--
EP 607607 A1 19940727 EP 1993-120842
19931223 <--
EP 607607 B1 19960918
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC,
NL, PT, SE
AT 143019 T 19961015 AT 1993-120842
19931223 <--
US 5670498 A 19970923 US 1995-527497
19950913 <--
PRIORITY APPLN. INFO.: JP 1992-344116 A
19921224 <--
US 1993-171602 B1
19931222 <--
OTHER SOURCE(S): MARPAT 122:81388
IC ICM C07D473-04
ICS A61K031-52
CC 28-16 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63
IT 27038-80-8P 27042-49-5P 151539-48-9P 151539-50-3P 155271-
32-2P
155271-33-3P 155271-84-4P 155271-85-5P 160434-22-0P
160434-41-3P
160434-42-4P 160434-43-5P 160434-44-6P 160434-45-7P
160434-46-8P
160434-47-9P 160434-48-0P 160441-79-2P
160471-62-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP
(Preparation); RACT
(Reactant or reagent)
(styrylxanthine adenosine A2 receptor antagonists)

L12 ANSWER 64 OF 64 CAPLUS COPYRIGHT 2009 ACS on STN
TI 1,3-Dialkyl-7-methyl-8-styrylxanthines as cerebral stimulants
ACCESSION NUMBER: 1971:100108 CAPLUS Full-text
DOCUMENT NUMBER: 74:100108
ORIGINAL REFERENCE NO.: 74:16301a,16304a
TITLE: 1,3-Dialkyl-7-methyl-8-styrylxanthines as
cerebral
stimulants
INVENTOR(S): Schweiss, Dieter; Long, Loren M.
PATENT ASSIGNEE(S): Parke, Davis and Co.
SOURCE: Ger. Offen., 14 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2037171	A	19710218	DE 1970-2037171	19700727 <--
DE 2037171	B2	19770922		

```
     US 3641010           A     19720208    US 1970-45594
19700611 <--
     BE 754007            A     19701231    BE 1970-754007
19700727 <--
     NL 7011094           A     19710202    NL 1970-11094
19700727 <--
     FR 2059577           A5    19710604    FR 1970-27624
19700727 <--
     FR 2059577           B1    19730810
     CH 512486            A     19710915    CH 1970-512486
19700727 <--
     CH 512487            A     19710915    CH 1970-512487
19700727 <--
     AT 297021            B     19720310    AT 1970-6822
19700727 <--
     GB 1280424           A     19720705    GB 1970-1280424
19700727 <--
PRIORITY APPLN. INFO.:                       US 1969-846264      A
19690730 <--
                                             US 1970-45594       A
19700611 <--
IC   C07D
CC   28 (Heterocyclic Compounds (More Than One Hetero Atom))
IT   31377-34-1P   31377-35-2P   31377-36-3P   31377-37-4P   31377-38-
5P
     31377-39-6P 31377-40-9P   31377-41-0P   31377-42-1P
     31377-43-2P   31377-44-3P   31377-45-4P   31377-46-5P
     RL: SPN (Synthetic preparation); PREP (Preparation)

     FILE 'CAPLUS' ENTERED AT 15:28:36 ON 22 JUL 2009
L13         121 S L12
L14           1 S L12 AND MIGRAINE/IT
L15           1 S L12 AND MIGRAINE?
L16           2 S L12 AND HEADACHE/IT
L17           0 S L16 AND (PY<2004 OR AY<2004 OR PRY<2004)
L18           2 S L12 AND HEADACH?
L19           2 S L12 AND ANALGES?
L20           0 S L19 NOT (L15 OR L16)
L21           1 S L12 AND ?DILAT?
L22           1 S L21 AND (PY<2004 OR AY<2004 OR PRY<2004)
L23           0 S L12 AND VESSEL?
L24           5 S L12 AND INFLAMMAT?
L25           2 S L24 AND (PY<2004 OR AY<2004 OR PRY<2004)
L26        6436 S MIGRAINE/IT
L27        1205 S L26 AND PARKINSON?
L28        1302 S L26 AND ALZHEIMER?
L29         516 S L27 AND (PY<2004 OR AY,2004 OR PRY<2004)
L30         516 S L27 AND (PY<2004 OR AY<2004 OR PRY<2004)
L31         302 S MIGRAINE? (L) PARKINSON?
L32         203 S L31 AND (PY<2004 OR AY<2004 OR PRY<2004)
L33         302 S MIGRAINE? (L) PARKINSON?
L34           7 S L33 AND ADENOSINE
L35           6 S L34 AND (PY<2004 OR AY<2004 OR PRY<2004)

L35  ANSWER 1 OF 6  CAPLUS  COPYRIGHT 2009 ACS on STN
TI   Preparation of triazolopyrazines as A2a adenosine receptor
     antagonists for the treatment of Parkinson's disease
```

ACCESSION NUMBER: 2004:902386 CAPLUS Full-text
DOCUMENT NUMBER: 141:395583
TITLE: Preparation of triazolopyrazines as A2a adenosine receptor antagonists for the treatment of Parkinson's disease
INVENTOR(S): Dowling, James; Yao, Gang; Chang, Hexi; Peng, Hairuo;
Vessels, Jeffrey; Petter, Russell C.; Kumaravel,
Gnanasambandam
PATENT ASSIGNEE(S): Biogen Idec Ma Inc., USA
SOURCE: PCT Int. Appl., 100 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004092177	A1	20041028	WO 2004-US11006	20040409 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG

L35 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN
TI Preparation of triazolotriazines and pyrazolotriazines as A2a adenosine receptor antagonists for the treatment of Parkinson's disease
ACCESSION NUMBER: 2004:902380 CAPLUS Full-text
DOCUMENT NUMBER: 141:395582
TITLE: Preparation of triazolotriazines and pyrazolotriazines
as A2a adenosine receptor antagonists for the treatment of Parkinson's disease
INVENTOR(S): Vu, Chi; Petter, Russell C.; Kumaravel, Gnanasambandam

PATENT ASSIGNEE(S): Biogen Idec Ma Inc., USA
SOURCE: PCT Int. Appl., 88 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004092170	A2	20041028	WO 2004-US11005	20040409 <--
WO 2004092170	A3	20050331		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

L35 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN
TI Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-AMP associated disorders
ACCESSION NUMBER: 2002:695727 CAPLUS Full-text
DOCUMENT NUMBER: 137:226646
TITLE: Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-AMP associated disorders
INVENTOR(S): Macor, John E.; Carlson, Kenneth E.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 91 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2002069905 A2 20020912 WO 2002-US6805
20020304 <--
WO 2002069905 A3 20031009
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,
CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD,
GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ,
OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR,
TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI,
FR, GB,
GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI,
CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG

L35 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN
TI Mol. and pharmacol. characterization of the murine seven-
transmembrane
receptor mHNEAA81
ACCESSION NUMBER: 2001:283994 CAPLUS Full-text
DOCUMENT NUMBER: 134:306969
TITLE: Mol. and pharmacol. characterization of the
murine
seven-transmembrane receptor mHNEAA81
INVENTOR(S): Taylor, Alexander H.; Ames, Robert S., Jr.;
Sarau,
Henry M.; Foley, James J.
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA;
Smithkline
Beecham PLC
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001027153	A1	20010419	WO 2000-US28304	20001013 <--
W: JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRIORITY APPLN. INFO.:			US 1999-159217P	P 19991013 <--
			US 2000-689582	A

```
20001012 <--
IC   ICM  C07K014-47
     ICS  C12N005-10; C12N005-16; C12N015-12; C12N015-63; C12N015-64;
          C12Q001-68
CC   6-2 (General Biochemistry)
     Section cross-reference(s): 1, 3, 13
IT   5542-28-9, Di-adenosine tetraphosphate
     RL: BPR (Biological process); BSU (Biological study,
unclassified); THU
     (Therapeutic use); BIOL (Biological study); PROC (Process); USES
(Uses)
        (AP4A, receptor agonist; mol. and pharmacol. characterization
of the
        murine seven-transmembrane receptor mHNEAA81)
REFERENCE COUNT:          1     THERE ARE 1 CITED REFERENCES AVAILABLE
FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE
RE FORMAT

L35  ANSWER 5 OF 6  CAPLUS  COPYRIGHT 2009 ACS on STN
TI   Preparation of pyrazole derivatives as adenosine A1 and A2
     antagonists
ACCESSION NUMBER:         1999:325927  CAPLUS  Full-text
DOCUMENT NUMBER:          130:338106
TITLE:                    Preparation of pyrazole derivatives as
                          adenosine A1 and A2 antagonists
INVENTOR(S):              Akahane, Atsushi; Kuroda, Satoru; Itani,
Hiromichi
PATENT ASSIGNEE(S):       Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE:                   PCT Int. Appl., 32 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 Japanese
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ----------------    ----   --------    --------------------   ----
----
     WO 9924424           A1    19990520    WO 1998-JP4892
19981028 <--
          W:  CA, CN, JP, KR, US
          RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,
MC, NL,
              PT, SE

L35  ANSWER 6 OF 6  CAPLUS  COPYRIGHT 2009 ACS on STN
TI   Preparation of (3-oxo-2,3-dihydropyridazin-6-yl)pyrazoles as
     adenosine antagonists
ACCESSION NUMBER:         1997:184649  CAPLUS  Full-text
DOCUMENT NUMBER:          126:171616
ORIGINAL REFERENCE NO.:   126:33165a,33168a
TITLE:                    Preparation of
                          (3-oxo-2,3-dihydropyridazin-6-yl)pyrazoles as
                          adenosine antagonists
INVENTOR(S):              Akahane, Atsushi; Kuroda, Satoru; Itani,
Hiromichi
```

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 78 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9701551	A1	19970116	WO 1996-JP1747	19960624 <--
W: JP, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
JP 11508267	T	19990721	JP 1996-504305	19960624 <--
PRIORITY APPLN. INFO.:			GB 1995-12964	A 19950626 <--
			AU 1996-8010	A 19960212 <--
			WO 1996-JP1747	W 19960624 <--

FILE 'REGISTRY' ENTERED AT 15:50:01 ON 22 JUL 2009
E KW 6002/CN
L36 1 S E27

FILE 'CAPLUS' ENTERED AT 15:50:21 ON 22 JUL 2009
L37 106 S L36
L38 0 S L37 AND PAIN?
L39 1 S L37 AND ANALGES?

L1 1 S E3

FILE 'CAPLUS' ENTERED AT 16:16:22 ON 22 JUL 2009
L2 86 S L1 AND ADENOSINE?
L3 40 S L2 AND (PY<2004 OR AY<2004 OR PRY<2004)
L4 8274 S MIGRAINE?
L5 37 S L4 AND ADENOSINE RECEPTORS/IT
L6 11 S L5 AND (PY<2004 OR AY<2004 OR PRY<2004)
L7 99 S L4 AND ADENOSINE?
L8 57 S L7 AND ANTAGONIST?
L9 28 S L8 AND A2?
L10 8 S L9 AND (PY,2004 OR AY<2004 OR PRY<2004)